Market Overview
The global biologics and biosimilars market was valued at USD 373.81 billion in 2024 and is projected to reach USD 690.86 billion by 2031, exhibiting a CAGR of 9.4% during the forecast period.
Biologics are complex, large-molecule drugs derived from living organisms, offering highly targeted therapeutic approaches. They include monoclonal antibodies, interferons, insulin, vaccines, and various cellular and gene therapies. Biosimilars are subsequent versions of innovator biologics that demonstrate no clinically meaningful differences in safety, purity, and potency.
690.86 billion by 2031 USD 373.81 billion in 2024
of 9.4%
Monoclonal Antibodies
Recombinant Proteins
Biosimilars
Other Biologics
Monoclonal Antibodies continue to dominate the biologics landscape due to their precision targeting capabilities and broad therapeutic applications across multiple disease areas, while biosimilars are gaining traction as cost-effective alternatives driving market expansion.
By Application
Oncology
Autoimmune Diseases
Infectious Diseases
Other Therapeutic Areas
Oncology applications command the largest market segment as biologics demonstrate remarkable efficacy in targeted cancer therapies and immunotherapy approaches, with autoimmune disease treatments showing accelerated adoption due to improved patient outcomes and reduced side-effect profiles.
Neuromonitoring Device Market
https://www.24lifesciences.com
Our Key Players
Novartis International AG (Switzerland)
Pfizer Inc. (USA)
Amgen Inc. (USA)
Merck & Co., Inc. (USA)
Samsung Bioepis (South Korea)
Celltrion Inc. (South Korea)
Eli Lilly and Company (USA)
https://www.24lifesciences.com
